No. |
KEGG PATHWAY * On map, Yellow: Drug target, Red: Disease-related |
KEGG GENES * |
KEGG DRUG * |
DrugBank |
指定難病告示番号 * |
1 | Acute myeloid leukemia 2 genes, 4 drugs (DrugBank) and 40 diseases shown |
1件: KIT |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
2 | Adherens junction 3 genes, 3 drugs (DrugBank) and 8 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
1件: FGFR1 |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
3 | Adipocytokine signaling pathway 1 gene, 3 drugs (DrugBank) and 37 diseases shown |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
4 | Adrenergic signaling in cardiomyocytes 1 gene, 1 drug (DrugBank) and 13 diseases shown |
1件: ADRB2 |
D02147 |
Salbutamol |
13件: 3, 11, 12, 13, 49, 85, 86, 89, 113, 228, 231, 256, 299 |
5 | AGE-RAGE signaling pathway in diabetic complications 1 gene, 1 drug (DrugBank) and 9 diseases shown |
1件: VEGFA |
D06409 |
Bevacizumab |
9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 |
6 | Alanine, aspartate and glutamate metabolism 4 genes, 1 drug (DrugBank) and 14 diseases shown |
4件: ABAT, ALDH5A1, GAD1, GAD2 |
D00399 |
Valproic Acid |
14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
7 | Aldosterone synthesis and secretion 3 genes, 1 drug (DrugBank) and 14 diseases shown |
3件: CACNA1G, CACNA1H, CACNA1I |
D00399 |
Valproic Acid |
14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
8 | AMPK signaling pathway 2 genes, 4 drugs (DrugBank) and 46 diseases shown |
1件: HMGCR |
D00434 |
Simvastatin |
19件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
9 | Apelin signaling pathway 1 gene, 3 drugs (DrugBank) and 37 diseases shown |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
10 | Arachidonic acid metabolism 1 gene, 1 drug (DrugBank) and 9 diseases shown |
1件: PTGS2 |
D00567 |
Celecoxib |
9件: 2, 3, 34, 46, 70, 89, 96, 161, 271 |
11 | Autophagy - animal 1 gene, 3 drugs (DrugBank) and 37 diseases shown |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
12 | Autophagy - other 1 gene, 3 drugs (DrugBank) and 37 diseases shown |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
13 | Axon guidance 2 genes, 2 drugs (DrugBank) and 12 diseases shown |
1件: ABL1 |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
2件: ABL1, SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
14 | Bacterial invasion of epithelial cells 1 gene, 1 drug (DrugBank) and 2 diseases shown |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
15 | beta-Alanine metabolism 3 genes, 1 drug (DrugBank) and 14 diseases shown |
3件: ABAT, GAD1, GAD2 |
D00399 |
Valproic Acid |
14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
16 | Bile secretion 1 gene, 1 drug (DrugBank) and 19 diseases shown |
1件: HMGCR |
D00434 |
Simvastatin |
19件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
17 | Bladder cancer 4 genes, 4 drugs (DrugBank) and 12 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
1件: FGFR3 |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
1件: VEGFA |
D06409 |
Bevacizumab |
9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 |
18 | Breast cancer 5 genes, 6 drugs (DrugBank) and 40 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
2件: FGFR1, FLT4 |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
1件: KIT |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
19 | Butanoate metabolism 4 genes, 1 drug (DrugBank) and 14 diseases shown |
4件: ABAT, ALDH5A1, GAD1, GAD2 |
D00399 |
Valproic Acid |
14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
20 | C-type lectin receptor signaling pathway 2 genes, 2 drugs (DrugBank) and 10 diseases shown |
1件: PTGS2 |
D00567 |
Celecoxib |
9件: 2, 3, 34, 46, 70, 89, 96, 161, 271 |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
21 | Calcium signaling pathway 7 genes, 5 drugs (DrugBank) and 30 diseases shown |
1件: ADRB2 |
D02147 |
Salbutamol |
13件: 3, 11, 12, 13, 49, 85, 86, 89, 113, 228, 231, 256, 299 |
3件: CACNA1G, CACNA1H, CACNA1I |
D00399 |
Valproic Acid |
14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
1件: PDGFRA |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
2件: PDGFRA, PDGFRB |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
22 | cAMP signaling pathway 2 genes, 2 drugs (DrugBank) and 19 diseases shown |
1件: ADRB2 |
D02147 |
Salbutamol |
13件: 3, 11, 12, 13, 49, 85, 86, 89, 113, 228, 231, 256, 299 |
1件: SSTR2 |
D00442 |
Octreotide |
8件: 67, 75, 84, 85, 89, 96, 193, 227 |
D06495 |
23 | Cell cycle 1 gene, 2 drugs (DrugBank) and 12 diseases shown |
1件: ABL1 |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
D09664 |
Saracatinib |
2件: 6, 89 |
24 | Cellular senescence 1 gene, 3 drugs (DrugBank) and 37 diseases shown |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
25 | Central carbon metabolism in cancer 8 genes, 6 drugs (DrugBank) and 40 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
5件: FGFR1, FGFR2, FGFR3, PDGFRA, PDGFRB |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
2件: KIT, PDGFRA |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
26 | cGMP-PKG signaling pathway 1 gene, 1 drug (DrugBank) and 13 diseases shown |
1件: ADRB2 |
D02147 |
Salbutamol |
13件: 3, 11, 12, 13, 49, 85, 86, 89, 113, 228, 231, 256, 299 |
27 | Chemical carcinogenesis 1 gene, 1 drug (DrugBank) and 9 diseases shown |
1件: PTGS2 |
D00567 |
Celecoxib |
9件: 2, 3, 34, 46, 70, 89, 96, 161, 271 |
28 | Chemokine signaling pathway 1 gene, 1 drug (DrugBank) and 2 diseases shown |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
29 | Choline metabolism in cancer 4 genes, 6 drugs (DrugBank) and 40 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
1件: PDGFRA |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
2件: PDGFRA, PDGFRB |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
30 | Chronic myeloid leukemia 1 gene, 2 drugs (DrugBank) and 12 diseases shown |
1件: ABL1 |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
D09664 |
Saracatinib |
2件: 6, 89 |
31 | Circadian entrainment 3 genes, 1 drug (DrugBank) and 14 diseases shown |
3件: CACNA1G, CACNA1H, CACNA1I |
D00399 |
Valproic Acid |
14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
32 | Colorectal cancer 2 genes, 4 drugs (DrugBank) and 37 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
33 | Cortisol synthesis and secretion 3 genes, 1 drug (DrugBank) and 14 diseases shown |
3件: CACNA1G, CACNA1H, CACNA1I |
D00399 |
Valproic Acid |
14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
34 | Cushing syndrome 4 genes, 2 drugs (DrugBank) and 16 diseases shown |
3件: CACNA1G, CACNA1H, CACNA1I |
D00399 |
Valproic Acid |
14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
35 | EGFR tyrosine kinase inhibitor resistance 9 genes, 8 drugs (DrugBank) and 42 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
5件: FGFR2, FGFR3, KDR, PDGFRA, PDGFRB |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
1件: PDGFRA |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
1件: VEGFA |
D06409 |
Bevacizumab |
9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 |
36 | Endocrine resistance 3 genes, 5 drugs (DrugBank) and 38 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
37 | Endocytosis 5 genes, 4 drugs (DrugBank) and 14 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
3件: FGFR2, FGFR3, PDGFRA |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
1件: PDGFRA |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
38 | Endometrial cancer 1 gene, 1 drug (DrugBank) and 5 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
39 | Epithelial cell signaling in Helicobacter pylori infection 2 genes, 2 drugs (DrugBank) and 6 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
40 | ErbB signaling pathway 4 genes, 6 drugs (DrugBank) and 41 diseases shown |
1件: ABL1 |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
2件: ABL1, SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
41 | Estrogen signaling pathway 2 genes, 2 drugs (DrugBank) and 6 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
42 | Fluid shear stress and atherosclerosis 3 genes, 3 drugs (DrugBank) and 12 diseases shown |
1件: KDR |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
1件: VEGFA |
D06409 |
Bevacizumab |
9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 |
43 | Focal adhesion 8 genes, 5 drugs (DrugBank) and 16 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
5件: FLT1, FLT4, KDR, PDGFRA, PDGFRB |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
1件: PDGFRA |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
1件: VEGFA |
D06409 |
Bevacizumab |
9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 |
44 | FoxO signaling pathway 1 gene, 1 drug (DrugBank) and 5 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
45 | GABAergic synapse 4 genes, 2 drugs (DrugBank) and 15 diseases shown |
3件: ABAT, GAD1, GAD2 |
D00399 |
Valproic Acid |
14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
46 | Gap junction 4 genes, 4 drugs (DrugBank) and 14 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
1件: PDGFRA |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
2件: PDGFRA, PDGFRB |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
47 | Gastric acid secretion 1 gene, 1 drug (DrugBank) and 8 diseases shown |
1件: SSTR2 |
D00442 |
Octreotide |
8件: 67, 75, 84, 85, 89, 96, 193, 227 |
D06495 |
48 | Gastric cancer 3 genes, 5 drugs (DrugBank) and 37 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
1件: FGFR2 |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
49 | Glioma 4 genes, 6 drugs (DrugBank) and 40 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
1件: PDGFRA |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
2件: PDGFRA, PDGFRB |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
50 | GnRH secretion 3 genes, 1 drug (DrugBank) and 14 diseases shown |
3件: CACNA1G, CACNA1H, CACNA1I |
D00399 |
Valproic Acid |
14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
51 | GnRH signaling pathway 2 genes, 2 drugs (DrugBank) and 6 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
52 | Growth hormone synthesis, secretion and action 2 genes, 4 drugs (DrugBank) and 41 diseases shown |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
1件: SSTR2 |
D00442 |
Octreotide |
8件: 67, 75, 84, 85, 89, 96, 193, 227 |
D06495 |
53 | Hematopoietic cell lineage 1 gene, 1 drug (DrugBank) and 11 diseases shown |
1件: KIT |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
54 | Hepatitis B 1 gene, 1 drug (DrugBank) and 2 diseases shown |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
55 | Hepatitis C 1 gene, 1 drug (DrugBank) and 5 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
56 | Hepatocellular carcinoma 2 genes, 4 drugs (DrugBank) and 37 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
57 | Herpes simplex virus 1 infection 2 genes, 4 drugs (DrugBank) and 38 diseases shown |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
58 | HIF-1 signaling pathway 4 genes, 6 drugs (DrugBank) and 39 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
1件: FLT1 |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
1件: VEGFA |
D06409 |
Bevacizumab |
9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 |
59 | Human cytomegalovirus infection 6 genes, 9 drugs (DrugBank) and 46 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
1件: PDGFRA |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
1件: PTGS2 |
D00567 |
Celecoxib |
9件: 2, 3, 34, 46, 70, 89, 96, 161, 271 |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
1件: VEGFA |
D06409 |
Bevacizumab |
9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 |
60 | Human immunodeficiency virus 1 infection 1 gene, 3 drugs (DrugBank) and 37 diseases shown |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
61 | Human papillomavirus infection 5 genes, 7 drugs (DrugBank) and 43 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
1件: PDGFRB |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
1件: PTGS2 |
D00567 |
Celecoxib |
9件: 2, 3, 34, 46, 70, 89, 96, 161, 271 |
1件: VEGFA |
D06409 |
Bevacizumab |
9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 |
62 | IL-17 signaling pathway 1 gene, 1 drug (DrugBank) and 9 diseases shown |
1件: PTGS2 |
D00567 |
Celecoxib |
9件: 2, 3, 34, 46, 70, 89, 96, 161, 271 |
63 | Inflammatory mediator regulation of TRP channels 1 gene, 1 drug (DrugBank) and 2 diseases shown |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
64 | Insulin resistance 1 gene, 3 drugs (DrugBank) and 37 diseases shown |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
65 | Insulin signaling pathway 1 gene, 3 drugs (DrugBank) and 37 diseases shown |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
66 | JAK-STAT signaling pathway 4 genes, 6 drugs (DrugBank) and 40 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
1件: PDGFRA |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
2件: PDGFRA, PDGFRB |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
67 | Kaposi sarcoma-associated herpesvirus infection 4 genes, 6 drugs (DrugBank) and 44 diseases shown |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
1件: PTGS2 |
D00567 |
Celecoxib |
9件: 2, 3, 34, 46, 70, 89, 96, 161, 271 |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
1件: VEGFA |
D06409 |
Bevacizumab |
9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 |
68 | Leishmaniasis 1 gene, 1 drug (DrugBank) and 9 diseases shown |
1件: PTGS2 |
D00567 |
Celecoxib |
9件: 2, 3, 34, 46, 70, 89, 96, 161, 271 |
69 | Longevity regulating pathway 1 gene, 3 drugs (DrugBank) and 37 diseases shown |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
70 | Longevity regulating pathway - multiple species 1 gene, 3 drugs (DrugBank) and 37 diseases shown |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
71 | MAPK signaling pathway 14 genes, 5 drugs (DrugBank) and 26 diseases shown |
3件: CACNA1G, CACNA1H, CACNA1I |
D00399 |
Valproic Acid |
14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
2件: KIT, PDGFRA |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
1件: VEGFA |
D06409 |
Bevacizumab |
9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 |
72 | Melanogenesis 1 gene, 1 drug (DrugBank) and 11 diseases shown |
1件: KIT |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
73 | Melanoma 4 genes, 3 drugs (DrugBank) and 13 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
3件: FGFR1, PDGFRA, PDGFRB |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
1件: PDGFRA |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
74 | Metabolic pathways 7 genes, 4 drugs (DrugBank) and 36 diseases shown |
4件: ABAT, ALDH5A1, GAD1, GAD2 |
D00399 |
Valproic Acid |
14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
1件: CYP19A1 |
D00964 |
Letrozole |
2件: 81, 89 |
1件: HMGCR |
D00434 |
Simvastatin |
19件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
1件: PTGS2 |
D00567 |
Celecoxib |
9件: 2, 3, 34, 46, 70, 89, 96, 161, 271 |
75 | MicroRNAs in cancer 8 genes, 9 drugs (DrugBank) and 46 diseases shown |
1件: ABL1 |
D09664 |
Saracatinib |
2件: 6, 89 |
2件: ABL1, PDGFRA |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
3件: FGFR3, PDGFRA, PDGFRB |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
1件: PTGS2 |
D00567 |
Celecoxib |
9件: 2, 3, 34, 46, 70, 89, 96, 161, 271 |
1件: VEGFA |
D06409 |
Bevacizumab |
9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 |
76 | Mitophagy - animal 1 gene, 1 drug (DrugBank) and 2 diseases shown |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
77 | mTOR signaling pathway 1 gene, 3 drugs (DrugBank) and 37 diseases shown |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
78 | Neuroactive ligand-receptor interaction 2 genes, 2 drugs (DrugBank) and 19 diseases shown |
1件: ADRB2 |
D02147 |
Salbutamol |
13件: 3, 11, 12, 13, 49, 85, 86, 89, 113, 228, 231, 256, 299 |
1件: SSTR2 |
D00442 |
Octreotide |
8件: 67, 75, 84, 85, 89, 96, 193, 227 |
D06495 |
79 | Neurotrophin signaling pathway 1 gene, 2 drugs (DrugBank) and 12 diseases shown |
1件: ABL1 |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
D09664 |
Saracatinib |
2件: 6, 89 |
80 | NF-kappa B signaling pathway 1 gene, 1 drug (DrugBank) and 9 diseases shown |
1件: PTGS2 |
D00567 |
Celecoxib |
9件: 2, 3, 34, 46, 70, 89, 96, 161, 271 |
81 | Non-small cell lung cancer 1 gene, 1 drug (DrugBank) and 5 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
82 | Ovarian steroidogenesis 2 genes, 2 drugs (DrugBank) and 10 diseases shown |
1件: CYP19A1 |
D00964 |
Letrozole |
2件: 81, 89 |
1件: PTGS2 |
D00567 |
Celecoxib |
9件: 2, 3, 34, 46, 70, 89, 96, 161, 271 |
83 | Oxytocin signaling pathway 3 genes, 3 drugs (DrugBank) and 13 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
1件: PTGS2 |
D00567 |
Celecoxib |
9件: 2, 3, 34, 46, 70, 89, 96, 161, 271 |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
84 | Pancreatic cancer 3 genes, 5 drugs (DrugBank) and 39 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
1件: VEGFA |
D06409 |
Bevacizumab |
9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 |
85 | Parathyroid hormone synthesis, secretion and action 2 genes, 2 drugs (DrugBank) and 7 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
1件: FGFR1 |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
86 | Pathogenic Escherichia coli infection 1 gene, 2 drugs (DrugBank) and 12 diseases shown |
1件: ABL1 |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
D09664 |
Saracatinib |
2件: 6, 89 |
87 | Pathways in cancer 12 genes, 9 drugs (DrugBank) and 46 diseases shown |
1件: ABL1 |
D09664 |
Saracatinib |
2件: 6, 89 |
3件: ABL1, KIT, PDGFRA |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
6件: FGFR1, FGFR2, FGFR3, FLT4, PDGFRA, PDGFRB |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
1件: PTGS2 |
D00567 |
Celecoxib |
9件: 2, 3, 34, 46, 70, 89, 96, 161, 271 |
1件: VEGFA |
D06409 |
Bevacizumab |
9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 |
88 | PD-L1 expression and PD-1 checkpoint pathway in cancer 2 genes, 4 drugs (DrugBank) and 37 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
89 | Phospholipase D signaling pathway 5 genes, 6 drugs (DrugBank) and 40 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
2件: KIT, PDGFRA |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
2件: PDGFRA, PDGFRB |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
90 | PI3K-Akt signaling pathway 12 genes, 7 drugs (DrugBank) and 41 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
2件: KIT, PDGFRA |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
1件: VEGFA |
D06409 |
Bevacizumab |
9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 |
91 | Platelet activation 1 gene, 1 drug (DrugBank) and 2 diseases shown |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
92 | Prolactin signaling pathway 1 gene, 1 drug (DrugBank) and 2 diseases shown |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
93 | Propanoate metabolism 1 gene, 1 drug (DrugBank) and 14 diseases shown |
1件: ABAT |
D00399 |
Valproic Acid |
14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
94 | Prostate cancer 6 genes, 6 drugs (DrugBank) and 40 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
4件: FGFR1, FGFR2, PDGFRA, PDGFRB |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
1件: PDGFRA |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
95 | Proteoglycans in cancer 6 genes, 7 drugs (DrugBank) and 40 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
2件: FGFR1, KDR |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
1件: VEGFA |
D06409 |
Bevacizumab |
9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 |
96 | Rap1 signaling pathway 12 genes, 5 drugs (DrugBank) and 16 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
2件: KIT, PDGFRA |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
1件: VEGFA |
D06409 |
Bevacizumab |
9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 |
97 | Ras signaling pathway 12 genes, 5 drugs (DrugBank) and 16 diseases shown |
1件: ABL1 |
D09664 |
Saracatinib |
2件: 6, 89 |
3件: ABL1, KIT, PDGFRA |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
1件: VEGFA |
D06409 |
Bevacizumab |
9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 |
98 | Regulation of actin cytoskeleton 7 genes, 4 drugs (DrugBank) and 14 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
5件: FGFR1, FGFR2, FGFR3, PDGFRA, PDGFRB |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
1件: PDGFRA |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
99 | Regulation of lipolysis in adipocytes 2 genes, 2 drugs (DrugBank) and 20 diseases shown |
1件: ADRB2 |
D02147 |
Salbutamol |
13件: 3, 11, 12, 13, 49, 85, 86, 89, 113, 228, 231, 256, 299 |
1件: PTGS2 |
D00567 |
Celecoxib |
9件: 2, 3, 34, 46, 70, 89, 96, 161, 271 |
100 | Relaxin signaling pathway 3 genes, 3 drugs (DrugBank) and 11 diseases shown |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
1件: VEGFA |
D06409 |
Bevacizumab |
9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 |
101 | Renal cell carcinoma 1 gene, 1 drug (DrugBank) and 9 diseases shown |
1件: VEGFA |
D06409 |
Bevacizumab |
9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 |
102 | Renin secretion 1 gene, 1 drug (DrugBank) and 13 diseases shown |
1件: ADRB2 |
D02147 |
Salbutamol |
13件: 3, 11, 12, 13, 49, 85, 86, 89, 113, 228, 231, 256, 299 |
103 | Retrograde endocannabinoid signaling 1 gene, 1 drug (DrugBank) and 9 diseases shown |
1件: PTGS2 |
D00567 |
Celecoxib |
9件: 2, 3, 34, 46, 70, 89, 96, 161, 271 |
104 | Rheumatoid arthritis 2 genes, 2 drugs (DrugBank) and 11 diseases shown |
1件: FLT1 |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
1件: VEGFA |
D06409 |
Bevacizumab |
9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 |
105 | Salivary secretion 1 gene, 1 drug (DrugBank) and 13 diseases shown |
1件: ADRB2 |
D02147 |
Salbutamol |
13件: 3, 11, 12, 13, 49, 85, 86, 89, 113, 228, 231, 256, 299 |
106 | Serotonergic synapse 1 gene, 1 drug (DrugBank) and 9 diseases shown |
1件: PTGS2 |
D00567 |
Celecoxib |
9件: 2, 3, 34, 46, 70, 89, 96, 161, 271 |
107 | Shigellosis 4 genes, 6 drugs (DrugBank) and 41 diseases shown |
1件: ABL1 |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
2件: ABL1, SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
1件: EGFR |
D03455 |
Cetuximab |
5件: 34, 51, 86, 89, 331 |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
108 | Signaling pathways regulating pluripotency of stem cells 3 genes, 1 drug (DrugBank) and 4 diseases shown |
3件: FGFR1, FGFR2, FGFR3 |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
109 | Small cell lung cancer 1 gene, 1 drug (DrugBank) and 9 diseases shown |
1件: PTGS2 |
D00567 |
Celecoxib |
9件: 2, 3, 34, 46, 70, 89, 96, 161, 271 |
110 | Steroid hormone biosynthesis 1 gene, 1 drug (DrugBank) and 2 diseases shown |
1件: CYP19A1 |
D00964 |
Letrozole |
2件: 81, 89 |
111 | Taurine and hypotaurine metabolism 2 genes, 1 drug (DrugBank) and 14 diseases shown |
2件: GAD1, GAD2 |
D00399 |
Valproic Acid |
14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
112 | Terpenoid backbone biosynthesis 1 gene, 1 drug (DrugBank) and 19 diseases shown |
1件: HMGCR |
D00434 |
Simvastatin |
19件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
113 | Th17 cell differentiation 1 gene, 3 drugs (DrugBank) and 37 diseases shown |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
114 | Thermogenesis 2 genes, 4 drugs (DrugBank) and 37 diseases shown |
1件: FGFR1 |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
115 | Thyroid hormone signaling pathway 2 genes, 4 drugs (DrugBank) and 38 diseases shown |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
116 | Tight junction 1 gene, 1 drug (DrugBank) and 2 diseases shown |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
117 | TNF signaling pathway 1 gene, 1 drug (DrugBank) and 9 diseases shown |
1件: PTGS2 |
D00567 |
Celecoxib |
9件: 2, 3, 34, 46, 70, 89, 96, 161, 271 |
118 | Transcriptional misregulation in cancer 1 gene, 1 drug (DrugBank) and 4 diseases shown |
1件: FLT1 |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
119 | Tuberculosis 1 gene, 1 drug (DrugBank) and 2 diseases shown |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
120 | Type I diabetes mellitus 2 genes, 1 drug (DrugBank) and 14 diseases shown |
2件: GAD1, GAD2 |
D00399 |
Valproic Acid |
14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
121 | Type II diabetes mellitus 2 genes, 4 drugs (DrugBank) and 44 diseases shown |
1件: CACNA1G |
D00399 |
Valproic Acid |
14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
1件: MTOR |
D02714 |
Everolimus |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
D00753 |
Sirolimus |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
D06068 |
Temsirolimus |
4件: 13, 34, 89, 331 |
122 | Valine, leucine and isoleucine degradation 1 gene, 1 drug (DrugBank) and 14 diseases shown |
1件: ABAT |
D00399 |
Valproic Acid |
14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
123 | VEGF signaling pathway 4 genes, 4 drugs (DrugBank) and 19 diseases shown |
1件: KDR |
D10481 |
Nintedanib |
4件: 51, 85, 89, 228 |
1件: PTGS2 |
D00567 |
Celecoxib |
9件: 2, 3, 34, 46, 70, 89, 96, 161, 271 |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
1件: VEGFA |
D06409 |
Bevacizumab |
9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 |
124 | Viral carcinogenesis 1 gene, 1 drug (DrugBank) and 2 diseases shown |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |
125 | Viral myocarditis 1 gene, 2 drugs (DrugBank) and 12 diseases shown |
1件: ABL1 |
D01441 |
Imatinib |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |
D09664 |
Saracatinib |
2件: 6, 89 |
126 | Yersinia infection 1 gene, 1 drug (DrugBank) and 2 diseases shown |
1件: SRC |
D09664 |
Saracatinib |
2件: 6, 89 |